Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Saturday . The company traded as high as $8.80 and last traded at $8.54, with a volume of 912811 shares changing hands. The stock had previously closed at $8.34.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on DRTS. Weiss Ratings reissued a "sell (d-)" rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Citigroup boosted their price target on Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Alpha Tau Medical in a report on Tuesday, March 10th. Piper Sandler reaffirmed a "neutral" rating and set a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Finally, Zacks Research raised Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.67.
Get Our Latest Analysis on DRTS
Alpha Tau Medical Trading Up 2.4%
The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The firm has a market capitalization of $724.36 million, a price-to-earnings ratio of -16.11 and a beta of 1.11. The company has a 50 day moving average price of $7.36 and a two-hundred day moving average price of $5.99.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, research analysts forecast that Alpha Tau Medical Ltd. will post -0.5 EPS for the current year.
Institutional Trading of Alpha Tau Medical
Several large investors have recently made changes to their positions in DRTS. Apella Capital LLC purchased a new stake in shares of Alpha Tau Medical during the fourth quarter worth approximately $1,892,000. Daytona Street Capital LLC purchased a new stake in shares of Alpha Tau Medical during the fourth quarter worth approximately $749,000. Mariner LLC increased its position in shares of Alpha Tau Medical by 185.8% during the third quarter. Mariner LLC now owns 123,250 shares of the company's stock worth $556,000 after purchasing an additional 80,129 shares in the last quarter. Millennium Management LLC increased its position in shares of Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company's stock worth $534,000 after purchasing an additional 70,081 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock worth $101,000 after purchasing an additional 21,677 shares in the last quarter. 2.65% of the stock is currently owned by hedge funds and other institutional investors.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
